Oral CBD treatment is associated with an anti-inflammatory gene expression signature in myeloid

cells of people living with HIV

Simone Marini[1,2]*, Amanda Huber[3], Melanie N. Cash[2,4], Marco Salemi[2,4], Robert L Cook[1,4], Paul

Borsa[5], and Carla N. Mavian[2,4]*.

*Corresponding authors: simone.marini@ufl.edu; cmavian@pathology.ufl.edu

1 Department of Epidemiology, University of Florida

2 Department of Pathology, University of Florida

3 Department of Radiation Oncology, University of Michigan

4 Emerging Pathogens Institute, University of Florida

5 Department of Applied Physiology & Kinesiology, University of Florida

Abstract

HIV-related comorbidities appear to be related to chronic inflammation, a condition characterizing

people living with HIV (PLWH). Prior work indicates that cannabidiol (CBD) might reduce

inflammation; however, the genetics underpinning of this effect are not well investigated. Our main

objective is to detect gene expression alterations in human peripheral blood mononuclear cells

(PBMCs) from PLWH after at least one month of CBD treatment.

We analyze ~41,000 PBMCs from three PLWH at baseline and after CBD treatment (27-60 days).

We obtained a coherent signature, characterized by an anti-inflammatory activity, of differentially

expressed genes in myeloid cells.

Our study shows how CBD is associated with alterations of gene expression in myeloid cells after

CBD treatment.

1 Introduction

Despite the advent of combined antiretroviral therapy (cART), residual HIV replication persists

and is associated with low-level immune activation driving chronic inflammation, one of the main

HIV-related complications. PLWH experience non-AIDS-defining illnesses associated with age

that are typical of older patients, such as presence of neurocognitive disorders, metabolic

syndrome, bone abnormality, non-HIV-associated cancers, and neurocognitive disorders.[1]

Chronic inflammation is a mechanism broadly involved in a plethora of diseases affecting aging

patients. Experts explicitly name this condition as *inflammageing*: Inflammageing is a pivotal risk

factor for dementia, chronic kidney disease, diabetes mellitus, cancer, depression, cardiovascular

diseases, and sarcopenia[2].

While the main HIV reservoir is known to be in resting memory CD4+ T-cells, several studies have

shown that a fraction of viral variants, detected either in residual viremia during therapy or at

rebound after therapy interruption, is genetically distinct from virus present in T-cell subsets.[3-5]

Myeloid cells, particularly monocytes and macrophages, have been described as active reservoirs

driving persistent low-level HIV expression and contributing to viral replication during rebound.[6-

10]

Monocytes are chronically activated during HIV infection, and are major mediators for the

development of comorbidities related to inflammageing, and specifically cardiovascular diseases,

neurocognitive disorder, and aging of the innate immune system.[11,12] Residual HIV viremia is likely

a source of monocyte activation as HIV proteins, such as p17, induce the production of

proinflammatory molecules by activated monocytes.[13] Inflammatory mediators produced by

monocytes, but not T-cell activation, predict low levels of chronic immune activation that persist

during cART treatment, a process named serious non-AIDS-defining illnesses associated with

age during viral suppression on cART,[14,15,16] highlighting the important role of monocyte activation

during cART-treated HIV infection.

Cannabis sativa is widely used for medical purposes and has anti-inflammatory activity. Cannabis

sativa and its cannabinoid derivatives, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD),

are largely used by people living with HIV (PLWH) to stimulate appetite, prevent weight loss (FDA

approved Marinol or Dronabinol), or manage chronic pain. CBD does not have psychoactive

effects and CBD products are available over the counter in all the United States[17,18]. CBD is a

compound investigated for its beneficial effect on inflammation;[19-20] but despite its widespread

use, the impact of CBD on health outcomes in PLWH remains understudied.[22] Here we investigate

the hypothesis that CBD is associated with a reduction of the expression of proinflammatory

genes in PBMCs of PLWH via single-cell RNA sequencing (scRNAseq).

Our results show a downregulated gene expression signature associated with CBD in myeloid

cells. Importantly, the great majority of these genes are known to be inflammation promoting.

Results

We sequenced six blood samples from three PLWH (IND1, IND2, IND3): for each individual, we

included a baseline (pre-CBD treatment) and a post-CBD treatment (27-60 days, ~67mg/day).

We identified eight distinct cell populations based on their expression profiles. We used

the Seurat package[23] for downstream analysis (Figure 1, A-D), applied after obtaining the results

from 10x Genomics Cell Ranger 3.0.0. Details of the procedure are reported in the Methods. After

quality control, we obtained 30,339 cells expressing 41,198 genes. Unsupervised clustering

revealed 10 cell clusters (Figure 1, A). Per-individual projection confirms that cells from each

individual are present in all the clusters (Figure 1, B).

We labeled the clusters based on specific genes that are characterizing cell populations (Figure

2). We obtained seven cell populations (Figure 1, D): *CD4* T cells (cluster 0; 8,622 cells expressing

IL-7R, *LEF1*, *CD28*, but not *CD8A*); *CD8* T cells (clusters 1 and 2; 11,303 cells expressing *CD8A*);

NKT cells (clusters 3 and 8; 4,279 cells expressing *NKG7*, *KLRD1*, *KLRG1*, and *CD8A*); NK cells

(cluster 4; 3,223 cells expressing *NKG7*, *KLRD1*, *KLRG1*, but not *CD8A*); Myeloid cells, including

monocytes (clusters 5 and 7; 2,277 cells expressing *LYZ*, *CD14*, *S100A8*, and *S100A9*); B cells

(cluster 6; 595 cells expressing *CD79A* and *CD79B*); and plasmablasts/plasma cells (cluster 9;

40 cells, expressing *JCHAIN*, *IGHG1*, *IGHA1*, *IGHA2*).

Myeloid cells carry a CBD-associated anti-inflammatory gene expression signature. We

identified differentially expressed genes (DEGs) in myeloid cells, reported in Table 1. Since the

number of myeloid cells is different for the three individuals, we provided DEGs for the cell

population considering all the individuals together, and for each distinct individual. We consider

as DEGs the six genes that are differentially expressed both overall (i.e., consider all the myeloid

cells) and in at least two of three PLWH (i.e., considering only the cell from a single person). All

the DEGs are under-expressed after CBD treatment. Five out of six genes show a positive role in

the inflammation process: *CXCL8* (interleukin-8) is a member of the chemokine family involved in

cell recruitment and activation under inflammatory conditions;[24] *EREG* is a proinflammatory gene

with a role in tissue healing and vascularization;[25] *JUN* and *FOS* are two genes expressed in

monocytes and macrophages involved in promoting inflammation,[26,27] and both are included as

markers in a recently general inflammatory macrophage activation phenotype encompassing

responses to HIV, sepsis, and SARS-CoV-2[28] *CCL3* is a proinflammatory gene and one of the

major HIV-suppressive factors produced by CD8+ T-cells and monocytes.[28,29] Other

proinflammatory genes appear among the top under-expressed genes (Table 1): *GPR183* plays

a role in attracting macrophages during viral inflammation;[30] *MIR23AHG* is a long non-coding

RNA gene promoting inflammation polarization in macrophages[31] and associated to chronic

inflammation in ulcerative colitis;[32] *TIPARP* is an antiviral gene, with a specific anti-HIV-1 effect in

monocytes;[33] *NAMPT* is a gene involved in the inflammatory responses activation with cytokine-

like behavior;[34] *IL1B* is a proinflammatory cytokine;[35-36] and *KLF6* is known to regulate

macrophage polarization towards the proinflammatory phenotype.[37] In summary, five out of six

DEGs and several of the top under-expressed genes are markedly involved in inflammatory

processes of myeloid cells. Taken together, this concerted underexpression can therefore be

interpreted as an anti-inflammatory signature associated with the CBD treatment.

STRING analysis indicates the DEG signature includes a protein interaction module. Using

our DEGs as input in the STRING database, a collection of known protein interactions,[38] with

highest stringency for the interaction score, we obtained a structured protein interaction module

centered on *JUN* and including five out of six genes (p-value 0.0001, Figure 3A). We proceeded

with a DEG pathway analysis by adding the highest-confidence STRING gene interactions to the

DEGs, and obtaining a network of 56 nodes (Figure 3B). The pathway analysis of the network

confirmed its proinflammatory nature, with focus on Mitogen-activated protein kinase (MAPK),

Cytokine, and Interleukine pathways. Among the top 20 Reactome[39] terms (ordered by p-value)

we find Signaling by Interleukines (p-value 7.5e-23); Cytokine Signaling in Immune system (p-

value 2e-21); Immune System (p-value 2e-17); Interleukine-10 signaling (p-value 2.1e-15);

Interleukin-4 and Interleukin-13 signaling (p-value 4.7e-15); NGF-stimulated transcription (p-value

2.4e-12); Activation of AP-1 family of transcription factors (p-value 4.3e-12); Signaling by NTRK1

(TRKA) (p-value 1e-11); MAPK targets/Nuclear events mediated by MAP kinases (p-value 2.5e-

11); Signaling by Receptor Tyrosine Kinases (p-value 1.15e-9); Toll Like Receptor 3 (TRL3)

Cascade (1.2e-9); Chemokine receptors bind chemokines (1.2e-9); and TRIF(TICAM1)-mediated

TLR4 signaling(1.5e-9). Supporting the above data suggesting a CBD-associated anti-

inflammatory signature in myeloid cells, it is known that IL-4 and IL-13 are cytokines known to

polarize myeloid cells towards an M2, anti-inflammatory phenotype[40]. Further, IL-10, an anti-

inflammatory molecule, can polarize myeloid cells to an M2c anti-inflammatory phenotype, and

M2 anti-inflammatory macrophages are known to produce this molecule[40,41]. All the retrieved

pathways are attached in Supplementary Table 1.

GO-based scoring and serology suggest a general anti-inflammatory shift in myeloid cell

gene expression. To further confirm the anti-inflammatory shift in myeloid cells, we designed an

inflammation score based on the gene expression of all the genes expressed in our dataset that

are listed under the Gene Ontology term *Positive regulation of inflammatory response*

(GO:0050729). The score decreases 12% after CBD in myeloid cells, from a median of 0.225 at

baseline to a median of 0.198 (p-value = 9.538e-08, Kolmogorov-Smirnov test). This decrement

is conserved by analyzing the score distribution per individual, as depicted in Figure 4, i.e., in

IND1, from 0.169 to 0.157, p-value = 0.004226; in IND2 from 0.147 to 0.05, p-value = 6.741e-08;

and in IND3 from 0.13 to 0.102, p-value = 3.524e-05.

The general reduction in inflammation is also indicated serologically. More specifically, the decline

in c-reactive protein (CRP) measure (baseline versus post-CBD treatment) was 10.25 and 8.2 for

IND1, 1.4 and 0.79 for IND2, 2.56 and 0.88 for IND3. The decline in erythrocyte sedimentation

rate 32 and 30 in IND1, 13 and 10 in IND2, 12 and 4 in IND3.

Inference of cell-cell communication variation. We used CellChat[42] to analyze the variation of

cell-cell communication between baseline and CBD conditions (Figure 5). The most affected

interactions involve myeloid cells, with decreased interactions from CD8 T cells, B cells, CD4 T

cells, NK cells, and with themselves; and with an increase of signals directed towards NKT cells.

Differentially expressed genes in other cell populations. Generally, non-myeloid cell

populations did not show differentially expressed genes, with the exception of B cells, where we

found *GNLY* under-expressed after CBD. *GNLY* is a cytotoxic gene that is typically expressed in

NK and T cells[41]. *GNLY* has shown the ability to promote the differentiation of monocytes into

dendritic cells, and is known for its marked inflammatory role.[43,44] Its decreased expression in the

B cell population is in line with a general shift towards a less proinflammatory gene expression

profile.

Discussion and Conclusions.

In this study, we measured gene expression at the single-cell level in PBMC samples obtained from three PLWH before (baseline) and after 27 to 60 days of CBD oil treatment. Our data indicate that CBD treatment is associated with decreased expression of a proinflammatory myeloid cell gene signature in PLWH on cART, enriched for specific inflammation pathways including MAPKs, cytokines, and interleukines. The CBD dosage of this study is within the dosage recommended by the CBD oil manufacturer, and is significantly lower than the one administered in other CBD clinical studies addressing, for example, psychosis or seizures.[46] Of note, the CBD oil used in this study is hemp-derived and therefore different from purified synthetic CBD such as Epidiolex.

This study does not come without limitations: We processed data for individuals with different lengths of CBD exposure; and IND3 did not follow the CBD regimen as diligently as IND1 and IND2. This seems to be reflected in the gene expression pattern (Table 1), where IND1 and IND2 show more marked and uniform effects. However, the gene expression variation in IND3 seems to be in line with the other individuals, with 14 out of the top 17 under-expressed genes following the same trends. Furthermore, the anti-inflammatory shift in myeloid cell gene expression in IND3 is also supported by the GO-based score (Figure 4) and the reduction in CRP and erythrocyte sedimentation. The extracted gene module is highly consistent with a diminished expression of proinflammatory genes and pathways; however, we did not find any specific connection between PLEKHG2 (one of the DEGs) and the inflammatory phenomenon in literature. Consistent with this, PLEKGH2 does not share interactions with the extended network of first-intreactors of the proinflammatory gene module (Figure 3B), even if we change the STRING threshold from 0.9 (highest confidence) to 0.15 (low confidence). A possible relation could consist of PLEKGH2 to be involved in monocyte migration, as PLEKHO2, another gene with a plekstrine homology

binding site, has been shown to be involved in this process[46]. Further investigations are needed

to confirm and understand if PLEKHG2 plays a role in the inflammatory pathways, and whether

its significantly decreased expression is associated with CBD.

Another limitation of this work is that, by limiting our age range, we did not include older adults

(65+). As the use of CBD and cannabis sativa for medical purposes by older adults is increasing[47],

future studies should also focus on this population.

While this study helps understand the genetic underpinning of CBD anti-inflammatory action, and

the potential of its anti-inflammatory effects, the molecular chain leading to inflammation reduction

remains to be unveiled. In future studies, we aim to target the extracted gene signature to better

characterize it, along with its molecular interactors and a measure of HIV viral load. As oral CBD

has very low bioavailability, in future studies we plan to measure serum levels of CBD and other

metabolites, and integrate the findings with the gene expression analysis in order to better

understand the molecular CBD machinery beyond the RNA level.

Methods

Recruitment. All individuals were recruited according to a UF IRB-approved protocol and

informed consent. *Main inclusion criteria included*: be older than 21 and younger than 60; be HIV+

and under antiretroviral therapy for 5+ years; report suppressed viral load in their most recent

check-up; tests negative for THC; and be practicing birth control. Main exclusion criteria included:

be suffering from conditions or taking medications that may impair the immune response; be

pregnant; be a current marijuana or CBD user; be taking anti-seizure medicines; having any

history of seizure disorder or head trauma; hepatic/liver diseases or renal diseases, such as

cirrhosis or multicystic dysplastic kidney; or cardiovascular disease, such as coronary heart

cerebrovascular diseases. We excluded all serious comorbidities. Eligibility for the study was

confirmed by a physician.

CBD treatment. CBD oil was provided by SunFlora, Inc, 411 19th Street South, St. Petersburg,

FL 33712. SunFlora is a third-party tested hemp-derived product manufacturing company. The

research team modified an existing FDA IND from SunFlora for this study. The hemp-extract

(SunMed™ Hemp Supplement) is a full spectrum CBD-rich formulation (~4-7%) containing very

low levels of THC (<0.3%), along with all naturally occurring cannabinoids, terpenes, and essential

oils from the plant extract. Flavoring agents have been added to ensure palatability. The tincture

solution is provided in a 30mL bottle (2000mg CBD). Each individual was provided two bottles,

each with a syringe dropper with instructions to administer the solution under the tongue twice

per day (BID), 8-12 hours apart (morning and evening) with food at the prescribed daily dosage

(1ml or ~67mg of CBD/day). The study protocol was approved by University of Florida's IRB. All

methods were performed in accordance with the relevant guidelines and regulations.

Sample collection. We sequenced six blood samples from three PLWH (IND 1-3): 2 females and

one male; mean age 44.3±9.5; reported cART treatments were valaciclovir,

dolutegravir/lamivudine, bictegravir/emtricitabine/tenofovir alafenamide, and darunavir/cobicistat.

All individuals reported a viral load of less than 200 copies of HIV per milliliter of blood at their last

check-up. Two samples are included in this study for each individual: a baseline (pre-CBD

treatment) and a post-CBD treatment. The post-CBD treatment sample was taken after 27 days

of treatment for IND1, with ~8% missed doses; after 70 days for IND2 (total 60 days of treatment),

with ~6% missed doses; and after 29 days for IND3 with ~60% missed doses. The planned

treatment was 60 days, however, it was not possible to consider samples after the first 30 days

from IND1 and IND3. Sedimentation Rate and CRP were obtained through the lab services of the

UF Health Shands Hospital.

Single-cell extraction and sequencing. *PBMC extraction*: Blood was collected in vacutainer

EDTA tubes and centrifuged within 30 minutes of collection at 200 x g for 10 minutes to separate

plasma and cellular fraction. Blood fraction was diluted with an equal amount of wash buffer

(Phosphate buffered saline [137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4];

1mM EDTA) and mixed by inversion 5 times. Diluted blood was carefully layered over

Lymphoprep Separation Media (Cellgro, Lincoln, NE) by gravity release. Tubes were centrifuged

at 400 x g for 30 minutes in a swinging bucket centrifuge with brake off. The PBMC layer was

collected, and cells were washed twice with wash buffer upon centrifugation at 400 x g for 10

minutes at room temperature with brake on. Next, cells were subjected to a lower speed wash at

200 x g for 10 minutes. Cells were filtered in a 70µM strainer (Fisher, Hampton, NH), counted and

frozen down using CryoStor Freezing Medium (Stem Cell Technologies, Vancouver, BC, Canada)

at ~15 million PBMCs per patient until they could be used for single-cell sequencing. *Sample*

preparation for single-cell RNA sequencing: Cryopreserved human peripheral blood mononuclear

cells (PBMCs) were prepared for 10x Genomics® Single Cell Sequencing according to the

manufacturer's protocol (Pleasanton, CA) with a few modifications. Briefly, the cells were quickly

thawed at 37°C following dropwise addition of warm complete medium (10% FBS in DMEM

(Fisher)). Following centrifugation, cells were washed once again with complete medium before

being subjected to dead cell removal using the Dead Cell Removal Kit (Miltenyi Biotech, Waltham,

MA) according to the manufacturer's protocol. Next, the cells were pelleted and washed with PBS,

0.04% BSA (400 µg/mL) twice before filtering through a Flowmi™ Tip Strainer (Fisher) and

counted to resuspend the cells at 1200 cells per µL for viability testing and library preparation.

Library construction and sequencing: The 10x Chromium Controller and Single Cell 3′ Library &

Gel Bead Kit v3 (10X Genomics) were used to construct barcoded single-cell RNA-Seq libraries

following the manufacturer's user guide (10X Genomics). Briefly, approximately 10,000 single

cells at 90% or greater viability are loaded onto the Chromium Controller. Single cells are captured

into Gel Bead-In Emulsions (GEM) where cell lysis and cDNA synthesis occur. All cDNAs

produced from a single cell will contain a unique DNA molecular barcode. Following

demulsification, mRNA-derived are recovered using SPRIselect reagent (Beckman). Library

construction was performed by fragmentation, end repair, A-tailing, adaptor ligation, and sample

index PCR, to which Illumina sequencing barcodes were added. After Ampure Beads clean up,

libraries were quantified by using Agilent TapeSation 4200 and qPCR quantification with NEB

Library Quanti Kit for Illumina (NEB). *Sequencing*: The libraries were sequenced on an Illumina

NovaSeq 6000 instrument using the S4 Reagent Kit v1.5, and aiming for 85,000 reads per cell.

We obtained 6,202.5 ± 1,604.09 cells per sample, and 572,746,422 ± 183,985,985 reads per

sample (Table 2). Count matrices were obtained with 10x Genomics Cell Ranger Single Cell

Software Suite. Library preparation and scRNASeq were performed at the UF Interdisciplinary

Center for Biotechnology Research (ICBR), University of Florida (UF). All quality control measures

were in the normal range.

Single-cell downstream analysis. The analysis is based on Seurat v4.2.0[23]. Where not

indicated, parameters were used at their default values. Briefly, we merged the six samples and

proceeded with quality control based on: number of different genes expressed per cell, counts

per cell, and fraction of mitochondrial content per cell. We based our downstream analysis on the

Seurat guidelines[23] and set the boundaries for the main parameters (genes expressed per cell

and mitochondrial content) on quality control, as included in the related Github repository. We

retained all cells expressing more than 750 genes and less than 5000, with a mitochondrial faction

lower than 0.15. We normalized the data and extracted the variable features, then scaled the data

regressing against the fraction of the mitochondrial content. We ran a PCA on the scaled data,

and used the first 25 components to calculate the UMAP projection and the neighboring cells.

Clusters were extracted with the Louvain algorithm (resolution = 0.1).

Differential gene expression was calculated with a Poisson model, minimal fraction of cells

expressing the gene = 0.25 and module of the base-2 logarithm of the fold change, |log2FC| >

0.5. For CBD signatures, we considered as DEGs the genes showing |log2FC| > 1, i.e., an

expression at least doubled or halved when comparing conditions, both globally (i.e., considering

the merged data set) and in at least two out of three individuals (i.e., considering cells from a

single individual).

Inflammation score. We used the Seurat function AddModuleScore to calculate the inflammation

score. We based the score on the genes listed in the GO term *positive regulation of inflammatory*

response (GO:0050729), considering genes that are expressed in our data (101 genes total).

Briefly, this score is based on the average expression levels of the GO genes, subtracted by the

aggregated expression of a control set of 100 randomly selected genes. To make the expression

levels comparable, genes are binned based on averaged expression (24 bins).

STRING database analysis. We used our six myeloid cell DEGs as the input for a STRING (v.

11.5)[38] analysis. To calculate the p-value, we proceeded empirically, as follows: We considered

all the human protein-protein interactions of STRING (~20 thousand proteins involved in ~12

billion interactions); we iteratively extracted 6 random genes, and counted how many interactions

were present in the subset with a score ≥ 0.9, the threshold of our analysis. If the random subset

had 4 or more interactions (our signature has 4), we counted a hit. We retrieved 5 hits over 50,000

iterations. Pathway analysis was conducted with STRING. First DEG interactors where added

with highest confidence (0.9) and allowing up to 50 interactions. All p-values are FDR-adjusted.

Cell-cell communication variation was inferred with CellChat[42]. Plasma cells were excluded by

the analysis because of the small size of the cell population. The cell-cell communication

database we used is CellChatDB based on Human cells. The population size parameter was set

to TRUE in the computeCommunProb function as suggested by the manual for non-sorted cells.

Other parameters were used at default value.

Data Availability statement

The code to obtain our results is available on github

(https://github.com/smarini/CBD_HIV_scRNAseq). Our data are available on GEO

(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228652).

Statements of funding

This work has been supported in part by the State of Florida's Consortium for Medical Marijuana

Clinical Outcomes Research granted to SM and CNM. This research and the authors align to the

Declaration of Helsinki. Trial: NCT05209867. 10x single-cell RNA sequencing, including library

preparation, was performed by the following UF ICBR Cores: Gene Expression & Genotyping

(GE) RRID:SCR_019145, NextGen DNA Sequencing (NS) RRID:SCR_019152, Bioinformatics

(BI) RRID:SCR_019120. We would like to thank The Southern HIV and Alcohol Research

Consortium (SHARC) for the help provided with the recruitment.

Author contributions

Conception/design of work: SM, RLC, PB, CNM; Acquisition of funding: SM, CNM;

Methods/analysis/interpretation of data: SM, AH, MNC, MS, CNM; Writing the first draft: SM,

MNC; Editing: AH, CNM; All authors read and approved the final manuscript.

Conflict of interest

NA

Figures and Tables

Figure 1. UMAP projection of the dataset. (A) Unsupervised clustering finds 10 cell clusters,

numbered 0 to 9. (B, C) Per-individual and per-condition colored projections. (D) Cell populations

labeled based on overexpressed genes in the clusters.

2   **Figure 2**. Gene expression violin plots for genes of interest to label cell clusters into populations:

3   Cluster 0, CD4 T cells; clusters 1 and 2, CD8 T cells; clusters 3 and 8, NKT cells; cluster 4, NK

4   cells; clusters 5 and 7, myeloid cells, including monocytes; cluster 6, B cells; and cluster 9,

5   plasmablasts/plasma cells.

Figure 3. String analysis. (A) The coherent nature of the anti-inflammatory protein module (DEGs in CBD versus baseline) is confirmed as five out of six DEG show interactions in the STRING database analysis, most stringent interaction threshold, p-value 0.0001. (B) The gene module expanded with its first interactors.

2   **Figure 4.** Violin and box plots of the inflammation score, per individual. The inflammation score

3   is calculated with the genes of GO:0050729 (Positive regulation of inflammatory response). CBD

4   score distributions are significantly lower in all individuals with p-values of 0.004226, 6.741e-08,

5   and 3.524e-05 for IND1, IND2, and IND3 respectively.

2   **Figure 5.** Cell-cell communication inferred by cell population.

Gene	log2FC (all)	log2FC IND1	log2FC IND2	log2FC IND3	Fraction Baseline (all)	Fraction CBD (all)	P-value (adj., all)
CXCL8	-1.78	-2.03	-2.03	*	0.558	0.344	0
EREG	-1.72	-1.87	-1.92	-0.83	0.304	0.149	0
PLEKHG2	-1.53	-1.92	-1.62	-0.63	0.571	0.21	0
G0S2	-1.24	-1.76	-0.14	0.15	0.21	0.21	1.27E-253
JUN	-1.23	-1.38	-0.83	-1.07	0.899	0.732	0
FOS	-1.15	-1.62	-1.16	-0.35	0.998	0.985	0
GPR183	-1.08	-1.42	-0.69	-0.39	0.427	0.21	1.82E-219
MIR23AHG	-1.06	-1.34	-0.96	-0.45	0.831	0.918	0
CCL3	-1.04	-1.32	-1.38	-0.39	0.366	0.174	6.62E-184
TIPARP	-1.04	-1.35	-0.88	-0.35	0.717	0.512	8.33E-275
ABCA1	-1.02	-1.46	-0.43	-0.35	0.646	0.418	1.6e-254
ENSG00000287124	-0.99	-1.06	-0.77	-0.73	0.645	0.501	1.33E-241
NAMPT	-0.98	-1.52	-0.47	*	0.986	0.989	0
ENSG00000253736	-0.97	-1.03	-1.01	-0.84	0.926	0.793	1.85E-301
IL1B	-0.96	-0.94	-1.76	-0.43	0.536	0.364	1.08E-269
KLF6	-0.96	-1.12	-1.01	-0.46	0.984	0.971	0
ANKRD28	-0.91	-0.97	-1.52	-0.28	0.601	0.402	1.83E-171

1   **Table 1**. Top under-expressed genes in myeloid cells (log2FC < -0.9, considering cells from all

2   the individuals). **Bold**: DEGs; underlined: genes of interest; log2FC = base-2 logarithm of the fold

3   change (CBD versus baseline); Fraction baseline = fraction of cells expressing the gene at

4   baseline; Fraction CBD = fraction of cells expressing the gene after CBD treatment; P-value (adj.)

5   = FDR adjusted p-value; values reported as * imply a logFC within the [-0.1, 0.1] interval.

individual	Condition	Total cells (CellRanger)	Total cells (after QC)	Total reads/sample
IND1	Baseline	5,356	4,335	501,043,269
IND1	CBD	5,435	3,766	417,536,116
IND2	Baseline	5,312	4,581	489,280,870
IND2	CBD	4,600	3,811	443,078,996
IND3	Baseline	8,991	7,547	891,314,194
IND3	CBD	7,521	6,299	694,225,088

1   **Table 2**. Total cells and reads per sample.

References

1. Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017 Jan;187(1):44–52.

2. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018 Sep;15(9):505–22.

3. Andrade VM, Mavian C, Babic D, Cordeiro T, Sharkey M, Barrios L, et al. A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proc Natl Acad Sci U S A. 2020 May 5;117(18):9981–90.

4. Vignoles M, Andrade V, Noguera M, Brander C, Mavian C, Salemi M, et al. Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses. Journal of Virus Eradication. 2021 Sep 1;7(3):100053.

5. Hendricks CM, Cash MN, Tagliamonte MS, Riva A, Brander C, Llano A, et al. Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells. Microbiology Spectrum. 2022 Jun 14;10(4):e01353-22.

6. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3879–84.

7. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012 Sep 21;37(3):377–88.

8. Stevenson M. Role of myeloid cells in HIV-1-host interplay. J Neurovirol. 2015 Jun 1;21(3):242–8.

9. Rodrigues V, Ruffin N, San-Roman M, Benaroch P. Myeloid Cell Interaction with HIV: A Complex Relationship. Front Immunol. 2017 Nov 30;8: 1698.

10. Wong ME, Jaworowski A, Hearps AC. The HIV Reservoir in Monocytes and Macrophages. Front Immunol. 2019 Jun 26;10:1435.

11. Merino KM, Allers C, Didier ES, Kuroda MJ. Role of Monocyte/Macrophages during HIV/SIV Infection in Adult and Pediatric Acquired Immune Deficiency Syndrome. Front Immunol. 2017 Dec 5;8:1693.

12. Liang H, Xie Z, Shen T. Monocyte activation and cardiovascular disease in HIV infection. Cell Mol Immunol. 2017 Dec;14(12):960–2.

13. Marini E, Tiberio L, Caracciolo S, Tosti G, Guzman CA, Schiaffonati L, et al. HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. Cell Microbiol. 2008 Mar;10(3):655–66.

14. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15;210(8):1248–59.

15. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014 Oct 15;210(8):1228–38.

16. Rodés B, Cadiñanos J, Esteban-Cantos A, Rodríguez-Centeno J, Arribas JR. Ageing with HIV: Challenges and biomarkers. Ebiomedicine. 2022 Mar;77:103896.

17. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, Jutras-Aswad D. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015 Oct;12:807-15.

18. Astray G, Mejuto JC, Xiao J, Simal-Gandara J. Benefits, toxicity and current market of cannabidiol in edibles. Critical Reviews in Food Science and Nutrition. 2021 Dec 30:1-3.

19. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants. 2020 Jan;9(1):21.

20. Sunda F, Arowolo A. A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol. The FASEB Journal. 2020;34(11):14083–92.

21. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorganic & Medicinal Chemistry. 2015 Apr 1;23(7):1377–85.

22. Costiniuk CT, Jenabian MA. Cannabinoids and inflammation: implications for people living with HIV. AIDS. 2019 Dec 1;33(15):2273–88.

23. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021 Jun 24;184(13):3573-3587.e29.

24. Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014 May;10(5):593–619.

25. Verma V, Khoury S, Parisien M, Cho C, Maixner W, Martin LJ, et al. The dichotomous role of epiregulin in pain. Pain. 2020 May;161(5):1052–64.

26. Veenhuis RT, Abreu CM, Shirk EN, Gama L, Clements JE. HIV replication and latency in monocytes and macrophages. Seminars in Immunology. 2021 Jan 1;51:101472.

27. Renoux F, Stellato M, Haftmann C, Vogetseder A, Huang R, Subramaniam A, et al. The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development. Cell Rep. 2020 Jun 30;31(13):107826.

28. Liu N, Jiang C, Cai P, Shen Z, Sun W, Xu H, et al. Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes. Cell Reports. 2021 Oct 5;37(1):109793.

29. Blondin-Ladrie L, Fourcade L, Modica A, Aranguren M, de Montigny N, Labbé AC, et al. Monocyte Gene and Molecular Expression Profiles Suggest Distinct Effector and Regulatory Functions in Beninese HIV Highly Exposed Seronegative Female Commercial Sex Workers. Viruses. 2022 Feb;14(2):361.

30. Foo CX, Bartlett S, Chew KY, Ngo MD, Bielefeldt-Ohmann H, Arachchige BJ, et al. GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. Eur Respir J. 2023 Mar 9;61(3):2201306.

31. Boucher A, Klopfenstein N, Hallas WM, Skibbe J, Appert A, Jang SH, et al. The miR-23a~27a~24-2 microRNA Cluster Promotes Inflammatory Polarization of Macrophages. The Journal of Immunology. 2021 Feb 1;206(3):540–53.

32. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, et al. MicroRNAs Are Differentially Expressed in Ulcerative Colitis and Alter Expression of Macrophage Inflammatory Peptide-2α. Gastroenterology. 2008 Nov 1;135(5):1624-1635.e24.

33. Kozaki T, Komano J, Kanbayashi D, Takahama M, Misawa T, Satoh T, et al. Mitochondrial damage elicits a TCDD-inducible poly(ADP-ribose) polymerase-mediated antiviral response. Proceedings of the National Academy of Sciences. 2017 Mar 7;114(10):2681–6.

34. Audrito V, Messana VG, Deaglio S. NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. Front Oncol. 2020 Mar 19;10:358.

35. Ren K, Torres R. Role of interleukin-1β during pain and inflammation. Brain Res Rev. 2009 Apr;60(1):57–64.

36. Henao-Mejia J, Elinav E, Strowig T, Flavell RA. Inflammasomes: far beyond inflammation. Nat Immunol. 2012 Apr;13(4):321–4.

37. Date D, Das R, Narla G, Simon DI, Jain MK, Mahabeleshwar GH. Kruppel-like Transcription Factor 6 Regulates Inflammatory Macrophage Polarization *. Journal of Biological Chemistry. 2014 Apr 11;289(15):10318–29.

38. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021 Jan 8;49(D1):D605–12.

39. Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, Griss J, Sevilla C, Matthews L, Gong C, Deng C. The reactome pathway knowledgebase 2022. Nucleic acids

research. 2022 Jan 7;50(D1):D687-92.

40. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol. 2008 Sep 15;181(6):3733-9.

41. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. The Journal of Immunology. 2008 May 1;180(9):5771-7.

42. Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV, Nie Q. Inference and analysis of cell-cell communication using CellChat. Nature communications. 2021 Feb 17;12(1):1088.

43. Sparrow E, Bodman-Smith MD. Granulysin: The attractive side of a natural born killer. Immunology Letters. 2020 Jan 1;217:126–32.

44. Wang XM, Zhang JY, Xing X, Huang HH, Xia P, Dai XP, et al. Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection. Cell Discov. 2022 Mar 28;8(1):1–17.

45. Pauli CS, Conroy M, Vanden Heuvel BD, Park SH. Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects. Front Pharmacol. 2020 Feb 25;11:63.

46. Powis G, Meuillet EJ, Indarte M, Booher G, Kirkpatrick L. Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:115024.

47. Victor B, Hager K, Stacy S. Re-legalizing cannabis for medical use in the USA. Journal of Public Health. 2022 Sep;44(3):679-84.